These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 11514705)

  • 1. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.
    Laking G; Price P
    Thorax; 2001 Sep; 56 Suppl 2(Suppl 2):ii38-44. PubMed ID: 11514705
    [No Abstract]   [Full Text] [Related]  

  • 2. Invasive aspergillosis mimicking stage IIIA non-small-cell lung cancer on FDG positron emission tomography.
    Wilkinson MD; Fulham MJ; McCaughan BC; Constable CJ
    Clin Nucl Med; 2003 Mar; 28(3):234-5. PubMed ID: 12592137
    [No Abstract]   [Full Text] [Related]  

  • 3. FDG PET: advantages for staging the mediastinum?
    Franzius C
    Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
    Erasmus JJ; Rohren E; Swisher SG
    Proc Am Thorac Soc; 2009 Apr; 6(2):171-9. PubMed ID: 19349485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of FDG PET in the management of NSCLC.
    Ukena D; Hellwig D
    Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET in lung cancer staging.
    Coleman RE
    Q J Nucl Med; 2001 Sep; 45(3):231-4. PubMed ID: 11788815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
    Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.
    Vansteenkiste JF
    Lung Cancer; 2005 Feb; 47(2):151-3. PubMed ID: 15639713
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography (PET) and combined imaging modalities for staging lung cancer.
    Scott WJ
    Surg Clin North Am; 2002 Jun; 82(3):477-95. PubMed ID: 12371581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET imaging in small cell lung cancer: any value?
    Lassen U
    Lung Cancer; 2002 Jul; 37(1):7. PubMed ID: 12057860
    [No Abstract]   [Full Text] [Related]  

  • 12. Value of positron emission tomography for lung cancer staging.
    Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
    Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography: lung cancer.
    Hagge RJ; Coleman RE
    Semin Roentgenol; 2002 Apr; 37(2):110-7. PubMed ID: 12134364
    [No Abstract]   [Full Text] [Related]  

  • 15. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
    Truong MT; Viswanathan C; Erasmus JJ
    J Thorac Imaging; 2011 May; 26(2):132-46. PubMed ID: 21508735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review.
    Mac Manus M; Hicks RJ
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1298-306. PubMed ID: 19028270
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers.
    Bryant AS; Cerfolio RJ
    J Thorac Cardiovasc Surg; 2006 Dec; 132(6):1363-8. PubMed ID: 17140957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET in staging lung cancer: how does it change the algorithm?
    Verhagen AF; Bootsma GP; Tjan-Heijnen VC; van der Wilt GJ; Cox AL; Brouwer MH; Corstens FH; Oyen WJ
    Lung Cancer; 2004 May; 44(2):175-81. PubMed ID: 15084382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
    Lee DH; Kim SK; Lee HY; Lee SY; Park SH; Kim HY; Kang KW; Han JY; Kim HT; Lee JS
    J Thorac Oncol; 2009 Jul; 4(7):816-21. PubMed ID: 19487962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Accuracy of positron emission tomography with fluorine-18-fluoro-deoxyglucose].
    Hellwig D; Gröschel A; Rentz K; Sybrecht GW; Kirsch CM; Ukena D
    Pneumologie; 2001 Aug; 55(8):363-6. PubMed ID: 11505287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.